GW Pharmaceuticals stock soars due to optimistic Epidiolex Phase III results

UK biopharma company GW Pharmaceuticals (AIM: GWP) has revealed positive findings in its Phase III study of Epidiolex (cannabidiol or CBD) for the treatment of Dravet syndrome, a rare and debilitating type of epilepsy.

Epidiolex achieved the study’s primary endpoint of significantly reducing convulsive seizures in children compared to placebo, the company announced on Monday, leading its stock price to rocket.

Treatment with the drug led to a median 39% reduction compared to 13% on placebo in what was the largest study ever conducted on Dravet syndrome. The average age of trial participants was 13 years.